Please complete Pre-test

Chapter 1 of 3

 

 

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In order to successfully develop targeted treatment plans and meet the clinical and disease needs of individual patients with acute myeloid leukemia (AML), one must understand the key safety and efficacy data. This activity will focus on practical expert recommendations for optimizing the use of new and recently approved agents and regimens. Hear from three experts as they review the most appropriate therapeutic strategies for individual patients.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Apply updated recommendations for diagnostic and prognostic evaluation of acute myeloid leukemia (AML) in clinical practice, including optimal use of molecular testing
  • Incorporate new and emerging therapies into the treatment paradigm to provide optimal care for patients with newly diagnosed or relapsed/refractory AML
  • Develop individualized treatment plans for patients with AML based on age, risk assessment, and other patient- or disease-related factors
  • Identify active clinical trials in both newly diagnosed and relapsed/refractory AML and incorporate referral to these trials when appropriate into treatment plans

Agenda

Chapter 1: Frontline Treatment in AML - Alexander Perl, MD

Chapter 2: Treating Relapsed/Refractory AML: How to Choose the Right Options - Jessica K. Altman, MD

Chapter 3: What’s Next: New Data and Clinical Trials That Could Change Treatment - Naval Daver, MD

Instructions for Participation and Credit

This activity is eligible for credit through July 10, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Naval Daver, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Naval Daver received his medical degree from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine in Houston, Texas. He is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

A clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis, Dr. Daver is the co/principal investigator for more than 25 ongoing clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing immune checkpoint- and vaccine-based approaches in AML, myelodysplastic syndromes (MDS), and myelofibrosis, and is conducting a number of these trials. Dr. Daver has published more than 100 peer-reviewed manuscripts. He has also authored numerous abstracts at national and international conferences.

Jessica K. Altman, MD
Associate Professor
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Dr. Jessica Altman received her medical degree from the University of Pittsburgh. She was an intern and resident in medicine at the University of Chicago Residency Program in Medicine, and a fellow in hematology and oncology at Northwestern University Medical School. Dr Altman also completed a master of science in clinical investigation at Northwestern University. She is currently an Associate Professor in the Department of Medicine, Division of Hematology/Oncology, at Northwestern University Feinberg School of Medicine. In addition, Dr. Altman is Director of the Leukemia Program for Northwestern Medicine, Developmental Therapeutics Institute, and Director of the Acute Leukemia Program of the Robert H. Lurie Comprehensive Cancer Center.

Dr. Altman has received board certification from the American Board of Internal Medicine (diplomate in internal medicine), the American Board of Internal Medicine (diplomate in medical oncology), and the American Board of Internal Medicine (diplomate in medical hematology). She is an NCCN Guidelines Panel member for AML and CML. In addition, Dr. Altman is on the editorial board of Leukemia & Lymphoma, a reviewer for Bone Marrow Transplantation, Blood, and Clinical Cancer Research, and an abstract reviewer for the American Society of Hematology (ASH). She has authored/co-authored numerous articles/abstracts on myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPN).

Alexander Perl, MD 
Associate Professor of Medicine
Abramson Cancer Center 
University of Pennsylvania
Philadelphia, Pennsylvania

Dr. Alexander Perl is a member of the leukemia program at the Abramson Cancer Center of the University of Pennsylvania, where he is an Associate Professor of Medicine. His particular expertise is in FLT3 inhibition as a therapeutic strategy for acute myeloid leukemia, clinical trials, and mechanisms of resistance to tyrosine kinase inhibitors.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Celgene Corporation, Helsinn, and Pfizer, Inc.



©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-030-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-030-126

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Naval Daver has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Agios, Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Karyopharm Therapeutics, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., and Sunesis. He has received grant support related to research activities from AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Inc., GlycoMimetics, Inc., ImmunoGen, Incyte, Karyopharm, Nohla Therapeutics, Novartis, Pfizer, SERVIER, and Sunesis.

Dr. Jessica Altman has received honoraria related to formal advisory activities from AbbVie Inc., Agios, Daiichi Sankyo, Inc., and Theradex Systems, Inc., as well as speakers’ bureau activities from the France Foundation. She has also disclosed a financial relationship with GlycoMimetics, Inc. (Data Safety and Monitoring Committee).

Dr. Alexander Perl has received honoraria as a consultant from AbbVie Inc., Actinium Pharmaceuticals, Inc., Arog Pharmaceuticals, Inc., Astellas Pharma US, Inc., Daiichi Sankyo, Inc., FORMA Therapeutics, Inc., and the Leukemia and Lymphoma Society, as well as formal advisory activities from Loxo Oncology and NewLink Genetics Corporation. He has received grant support related to research activities from AbbVie, Astellas, Bayer AG, Daiichi Sankyo, and Novartis AG.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Wilma Guerra, Program Director, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.